A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
Review Will Determine Whether Access To Biogen's SMA Treatment Will Be Expanded
NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.
You may also be interested in...
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
It has taken 17 months of negotiations but soon 600-1,200 people in the UK may be able to get Biogen's spinal muscular atrophy therapy now that an access agreement has been inked.
Advicenne withdrew its orphan drug designation application for Sibnayal over concerns that a key study was not designed to compare the product to standard of care.